HiFiBiO Therapeutics, a clinical-stage global biotech, is pioneering a unique high-resolution translational platform (DIS®) to enhance the probability of success for immunotherapies
Read more about HiFiBiO Therapeutics Read More
Our Science
We apply single cell science at every stage of drug development from target discovery to predictive biomarkers, enabling rapid advancement of new therapeutics into the clinic.
Read more
Our SOAR Values
We unite under a shared mission to SOAR to new heights in science and healthcare.
Read more
Paris, France, and Cambridge, MA, December 11, 2023 – HiFiBiO Therapeutics, a leading clinical stage global biotech company dedicated to advancing patient outcomes through single-cell precision, proudly announces its strategic collaboration with clinical institutions and life science companies in the formation of a groundbreaking consortium under the France 2030 Initiative. This visionary project, named REMISSION … Continued
Cambridge, MA, November 8, 2023 – HiFiBiO Therapeutics, a clinical stage global biotech company with the goal of improving patient lives with single-cell precision, today announced that BioTech Breakthrough has named its proprietary translational platform, Drug Intelligence Science (DIS®) as the BioTech AI Innovation of the Year. The annual awards program features the best and … Continued
Drug Intelligence Science (DIS®) – Pioneering a High-Resolution Translational Platform to Enhance Probability of Success for Drug Discovery and Development CAMBRIDGE, MA., – October 23, 2023 – HiFiBiO Therapeutics Founder, Chairperson, and CEO Liang Schweizer presents, in the peer-reviewed journal Drug Discovery Today, the company’s proprietary translational platform Drug Intelligence Science (DIS®), highlighting its potential … Continued
Paris, France, and Cambridge, MA, December 11, 2023 – HiFiBiO Therapeutics, a leading clinical stage global biotech company dedicated to advancing patient outcomes through single-cell precision, proudly announces its strategic collaboration with clinical institutions and life science companies in the formation of a groundbreaking consortium under the France 2030 Initiative. This visionary project, named REMISSION … Continued
HiFiBiO Therapeutics single-cell focused platform identifies translationally relevant targets, enables rapid drug development, and matches treatments to patients for better clinical outcomes
